Health & Mind

The Psychedelic Renaissance

After Decades of Prohibition, Psychedelic Drugs Are Returning to the Clinic — with Remarkable Results

Julia Hoffman

Psychiatrist and researcher at Imperial College London's Centre for Psychedelic Research, conducting clinical trials of psilocybin for treatment-resistant depression.

February 10, 2026·8 min read

The Psychedelic Renaissance

Psilocybin, MDMA, and ketamine are showing remarkable efficacy in clinical trials for treatment-resistant depression, PTSD, and addiction. After decades of prohibition that halted research, a new generation of scientists is rediscovering the therapeutic potential of psychedelic drugs — and challenging our understanding of consciousness and mental illness.

TOPICS

psychedelicsmental healthpsilocybinMDMAtherapy

More from Health & Mind

View all Health & Mind articles →

Health & Mind

Why Do We Dream?

Every night, as your body lies still, your brain stages an elaborate private cinema — conjuring faces, landscapes, and emotions from nothing. After a century of research, scientists are finally beginning to decode what dreams are actually for, and the answers are stranger and more profound than anyone expected.

Sophia Liang·15 min read

Society & Culture

The Loneliness Epidemic

Despite living in the most connected era in human history, rates of loneliness and social isolation have reached epidemic proportions across the developed world. Understanding this paradox requires examining the difference between connection and genuine community.

Amara Osei·13 min read

Health & Mind

The Gut-Brain Axis

The trillions of microorganisms living in your digestive system do far more than help you digest food. Emerging research reveals that the gut microbiome communicates directly with the brain, influencing mood, cognition, and the risk of psychiatric disorders.

Priya Nair·15 min read

View all Health & Mind articles →